# Manifold Bio

**Canonical:** https://apis.io/providers/manifold-bio/  
**Website:** https://www.manifold.bio/  
**APIs profiled:** 0

Manifold Bio is a biotechnology company developing tissue-targeted biologic medicines. It runs a high-throughput in vivo discovery engine that pairs massively multiplexed in vivo screening — using mCode protein barcodes read out by DNA sequencing — with AI-powered protein and antibody design (mBER) and engineered mShuttle delivery vehicles. Its pipeline targets CNS diseases such as Alzheimer's and Parkinson's (amyloid-beta, tau, alpha-synuclein) and peripheral cardiometabolic disease. Backed by Playground Global. The company publishes no public developer API, SDK, documentation, or event surface as of this enrichment pass.

## Kin Score — 5.0 / 100 (minimal)

Scored 2026-08-20 under rubric 0.12.0. Trend: flat (+0.0 from 5.0).

| Facet | Score |
|---|---|
| Discoverability | 50.0 |
| Contract Quality | 0.0 |
| Governance | 0.0 |
| Contract Governance | 0.0 |
| Operational Transparency | 0.0 |
| Developer Ergonomics | 0.0 |
| Commercial Clarity | 0.0 |
| Access Clarity | 0.0 |

## Agent readiness — 0.0 (human-only)

| Dimension | Value |
|---|---|
| Spec Presence | no |
| Agentic Access | no |
| Reversibility Documented | no |
| MCP Server | no |
| Auth Clarity | no |
| Idempotency | no |
| Error Semantics | no |
| OpenAPI Examples | no |
| Rate Limit Signal | no |
| Event Surface Described | no |
| Agent Skills | no |
| Well Known Catalog | no |
| Consent Identity | no |
| Agent Card | no |
| Dry Run Mode | no |

## Access

Unknown — onboarding: unknown, pricing: unknown, trial: no (confidence: low).

## Security (1)

- **Manifold Bio Domain Security** — TLSv1.3 · HSTS

## Tags

Company, Engineered Biology, Biotechnology, Drug Discovery, Protein Design, Therapeutics, Antibody Engineering, Artificial Intelligence

---

Profiled by [API Evangelist](https://apievangelist.com) and published on [APIs.io](https://apis.io/providers/manifold-bio/). Scores are computed from the provider's own public artifacts under a published rubric.